Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

Journal of Pathology

Volumn 231, Issue 1, 2013, Pages 21-34

  Bashashati, Ali ^a   Ha, Gavin ^a   Tone, Alicia ^a   Ding, Jiarui ^a,b   Prentice, Leah M ^a   Roth, Andrew ^a   Rosner, Jamie ^a   Shumansky, Karey ^a   Kalloger, Steve ^a   Senz, Janine ^a   Yang, Winnie ^a   McConechy, Melissa ^a   Melnyk, Nataliya ^a   Anglesio, Michael ^a   Luk, Margaret T Y ^c   Tse, Kane ^a   Zeng, Thomas ^a   Moore, Richard ^a   Zhao, Yongjun ^a   Marra, Marco A ^a   Gilks, Blake ^c   Yip, Stephen ^b   Huntsman, David G ^a,b   McAlpine, Jessica N ^b   Shah, Sohrab P ^a,b   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Clonal evolution; High grade serous ovarian cancer; Intratumoural heterogeneity

Indexed keywords

BETA CATENIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 4 5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; AMPLICON; AMPLICON DEEP SEQUENCING; ANEUPLOIDY; ARTICLE; CANCER PATIENT; CELL POPULATION; CLINICAL ARTICLE; COPY NUMBER VARIATION; DISEASE SEVERITY; DISTANT METASTASIS; ENDOMETRIOID CARCINOMA; EXOME; EXOME SEQUENCING; FALLOPIAN TUBE LESION; FEMALE; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CONSERVATION; GENETIC VARIABILITY; GENOME; HIGH GRADE SEROUS OVARIAN CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; UTERINE TUBE; UTERINE TUBE DISEASE; UTERINE TUBE TUMOR;

EID: 84885092663     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4230     Document Type: Article

References (40)

1. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
2. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high-grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
3. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
4. Risch HA, McLaughlin JR, Cole DEC, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-1706.
5. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002; 94: 61-67.
6. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94: 1396-1406.
7. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-173.
8. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
9. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010; 34: 829-836.
10. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17-17.
11. McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 2012; 25: 740-750.
12. Nowell PC. The clonal evolution of tumor cell populations. Science (NY) 1976; 194: 23-28.
13. Fearon ER, Vogelstein B, others. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
14. Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 2003; 4: 4-6.
15. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997; 57: 1597-1604.
16. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724.
17. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
18. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
19. Losi L, Baisse B, Bouzourene H, et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005; 26: 916-922.
20. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
21. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010; 41: 914-917.
22. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004; 4: 227-235.
23. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
24. Khalique L, Ayhan A, Weale ME, et al. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 2007; 211: 286-295.
25. Khalique L, Ayhan A, Whittaker JC, et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer 2009; 124: 1579-1586.
26. Cooke SL, Ng CKY, Melnyk N, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010; 29: 4905-4913.
27. Castellarin M, Milne K, Zeng T, et al. Clonal evolution of highgrade serous ovarian carcinoma from primary to recurrent disease. J Pathol 2013; 229: 515-524.
28. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
29. Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.
30. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-993.
31. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
32. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Translat Med 2012; 4: 136ra68.
33. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536.
34. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109-115.
35. Catasus L, Bussaglia E, Rodriguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of β-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360-1368.
36. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
37. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
38. Bashashati A, Haffari G, Ding J, et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol 2012; 13: R124.
39. Cowin PA, George J, Fereday S, et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res 2012; 72: 4060-4073.
40. Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012; 10: 296-306.